Zacks: Analysts Anticipate Danaher Co. (DHR) Will Announce Quarterly Sales of $4.53 Billion

Equities research analysts expect Danaher Co. (NYSE:DHR) to report sales of $4.53 billion for the current quarter, according to Zacks. Eight analysts have issued estimates for Danaher’s earnings, with estimates ranging from $4.48 billion to $4.57 billion. Danaher reported sales of $4.21 billion during the same quarter last year, which would suggest a positive year over year growth rate of 7.6%. The company is expected to issue its next quarterly earnings report on Thursday, April 19th.

According to Zacks, analysts expect that Danaher will report full-year sales of $4.53 billion for the current year, with estimates ranging from $19.11 billion to $19.74 billion. For the next fiscal year, analysts expect that the firm will post sales of $20.24 billion per share, with estimates ranging from $19.80 billion to $20.55 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Danaher.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, topping the consensus estimate of $1.16 by $0.03. The firm had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The company’s quarterly revenue was up 10.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.05 earnings per share.

DHR has been the subject of a number of research analyst reports. Citigroup increased their price target on Danaher to $107.00 and gave the company a “buy” rating in a research report on Friday, December 15th. Robert W. Baird reissued a “buy” rating on shares of Danaher in a research report on Friday, January 12th. Royal Bank of Canada reissued a “hold” rating and issued a $96.00 target price on shares of Danaher in a research report on Thursday, January 4th. Stifel Nicolaus raised their target price on Danaher from $110.00 to $115.00 and gave the stock a “buy” rating in a research report on Wednesday, January 31st. Finally, Credit Suisse Group raised their target price on Danaher from $93.00 to $96.00 and gave the stock an “outperform” rating in a research report on Friday, October 20th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $100.13.

Shares of Danaher (NYSE:DHR) opened at $96.70 on Tuesday. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $67,270.00, a P/E ratio of 27.63, a P/E/G ratio of 2.20 and a beta of 1.04. Danaher has a 52-week low of $78.97 and a 52-week high of $104.82.

The business also recently declared a quarterly dividend, which was paid on Friday, January 26th. Stockholders of record on Friday, December 29th were issued a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.58%. The ex-dividend date of this dividend was Thursday, December 28th. Danaher’s payout ratio is currently 16.00%.

In related news, CFO Daniel L. Comas sold 62,989 shares of Danaher stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the completion of the sale, the chief financial officer now owns 227,805 shares of the company’s stock, valued at $23,226,997.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP William K. Daniel sold 131,066 shares of Danaher stock in a transaction on Friday, February 2nd. The shares were sold at an average price of $102.05, for a total value of $13,375,285.30. Following the sale, the executive vice president now directly owns 270,523 shares of the company’s stock, valued at approximately $27,606,872.15. The disclosure for this sale can be found here. Insiders sold 274,913 shares of company stock valued at $27,729,293 over the last ninety days. Corporate insiders own 12.20% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. Aries Wealth Management bought a new stake in Danaher during the fourth quarter valued at $206,000. Fishman Jay A Ltd. MI boosted its stake in Danaher by 6.2% during the fourth quarter. Fishman Jay A Ltd. MI now owns 23,842 shares of the conglomerate’s stock valued at $2,213,000 after buying an additional 1,400 shares during the period. Bank of The Ozarks boosted its stake in Danaher by 12.0% during the fourth quarter. Bank of The Ozarks now owns 7,385 shares of the conglomerate’s stock valued at $685,000 after buying an additional 793 shares during the period. Watch Point Trust Co boosted its stake in Danaher by 2.9% during the fourth quarter. Watch Point Trust Co now owns 20,249 shares of the conglomerate’s stock valued at $1,879,000 after buying an additional 562 shares during the period. Finally, Calton & Associates Inc. bought a new stake in Danaher during the fourth quarter valued at $114,000. 76.19% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Danaher Co. (DHR) Will Announce Quarterly Sales of $4.53 Billion” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/06/zacks-analysts-anticipate-danaher-co-dhr-will-announce-quarterly-sales-of-4-53-billion.html.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Get a free copy of the Zacks research report on Danaher (DHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply